Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - prednisolone, quantity: 25 mg - tablet, uncoated - excipient ingredients: wheat starch; magnesium stearate; gelatin; lactose monohydrate; maize starch; propyl hydroxybenzoate - indications as at 26 march 1997 : wherever corticosteroid therapy is indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - metoclopramide hydrochloride monohydrate, quantity: 10.537 mg (equivalent: metoclopramide hydrochloride, qty 10 mg) - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; lactose monohydrate; pregelatinised maize starch; magnesium stearate; maize starch - indications as at 10 august 1994: adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. intramuscular administration of maxolon facilitates the absorption of a range of drugs including the absorption of aspirin in people with migraine. maxolon has been found useful in the management of gastric retention after gastric surgery. maxolon may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, maxolon should be discontinued. young adults and children: the use of maxolon in patients under 20 years should be restricted to the following s

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - orphenadrine citrate, quantity: 35 mg; paracetamol, quantity: 450 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; pregelatinised maize starch; magnesium stearate; gelatin - tension headache, occipital headaches associated with spasm of skeletal muscles in the region of the head and neck. acute and traumatic conditions of the limbs and trunk; sprains, strains, whiplash injuries, acute torticollis, prolapsed intervertebral disc.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

aquarium pharmaceuticals - malachite green (zinc free oxalate) | acriflavine - antibiotic & related - fish aquarium freshwater | cold water | tropical - not applicable (vet)

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - bisacodyl 5mg - enteric coated tablet - 5 mg - active: bisacodyl 5mg excipient: calcium carbonate colloidal silicon dioxide gelatin lactose monohydrate macrogol 6000 magnesium stearate methacrylic acid copolymer microcrystalline cellulose povidone   purified talc   quinoline yellow silicon sodium starch glycolate starch sucrose

New Zealand - English - Medsafe (Medicines Safety Authority)

noumed pharmaceuticals limited - codeine phosphate hemihydrate 15mg;  ;  ;  ;   - tablet - 15 mg - active: codeine phosphate hemihydrate 15mg         excipient: lactose monohydrate magnesium stearate maize starch - codeine phosphate is indicated for: the relief of mild to moderate pain (including pain associated with terminal illness, post-operative pain and headache), the relief of symptoms of diarrhoea (except diarrhoea caused by poisoning),

New Zealand - English - Medsafe (Medicines Safety Authority)

link pharmaceuticals ltd - colistimethate sodium 384.6 mg/ml - powder for injection - 150 mg/2ml - active: colistimethate sodium 384.6 mg/ml - the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli; particularly when the infection is caused by sensitive strains of pseudomonas aeruginosa, and the following gram-negative organisms; aerobacter aerogenes, escherichia coli, klebsiella pneumoniae. pending results of appropriate bacteriologic cultures and sensitivity tests, colistimethate sodium may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms.

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - acetazolamide 250mg;   - tablet - 250 mg - active: acetazolamide 250mg   excipient: calcium hydrogen phosphate dihydrate magnesium stearate povidone sodium starch glycolate starch - for adjunctive treatment of: oedema due to congestive heart failure; drug induced oedema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - nitrazepam 5mg;   - tablet - 5 mg - active: nitrazepam 5mg   excipient: lactose monohydrate magnesium stearate maize starch - nitrazepam is indicated in adults for: · short term treatment of insomnia when it is severe, disabling or subjecting the individual to unacceptable distress, where daytime insomnia is acceptable.

New Zealand - English - Medsafe (Medicines Safety Authority)

noumed pharmaceuticals limited - pethidine hydrochloride 50mg;   - tablet - 50 mg - active: pethidine hydrochloride 50mg   excipient: acacia lactose monohydrate magnesium stearate maize starch - for the relief of most types of moderate to severe pain. as it has some antispasmodic activity it may be the analgesic of choice in renal colic, bilary colic and acute pancreatitis.